Omrix shares surge on report of buyout offers

Shares of New York-based Omrix Biopharmaceuticals shot up on a report in the Israeli-based Globes that a New York hedge fund had offered to acquire the biotech company for $25 a share--a 13 percent premium on its Friday close. Citing unnamed sources, the Globes report also said that Omrix had rejected a buyout bid by Johnson & Johnson. Omrix does R&D work in Israel. Omrix makes products that control bleeding.

--read the AP report

Related Articles:
OMRIX Biopharmaceuticals Receives FDA Approval for Thrombin
Omrix outlines plan for $55M offering